#1 Clinical Trials Search in Europe

Bexotegrast

Bexotegrast, also known as PLN-74809, is an innovative drug currently being studied in clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). This article explores the ongoing research into Bexotegrast’s potential to improve lung function and quality of life for patients with this challenging respiratory condition.

Table of Contents

What is Bexotegrast?

Bexotegrast, also known as PLN-74809, is a new medication being developed to treat idiopathic pulmonary fibrosis (IPF). It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with this serious lung condition.[1]

What is Idiopathic Pulmonary Fibrosis (IPF)?

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that causes scarring (fibrosis) of the lungs. The term “idiopathic” means the cause is unknown. This scarring makes it difficult for the lungs to work properly, leading to breathing problems that worsen over time.[1]

How Bexotegrast Works

While the exact mechanism of action is not detailed in the provided information, Bexotegrast is being studied as a potential treatment for IPF. It is believed to target the underlying processes that cause lung scarring in IPF patients.[1]

Clinical Trial Details

The clinical trial for Bexotegrast, known as BEACON-IPF, is a Phase 2b/3 study. This means it’s in an advanced stage of testing, looking at both the right dose to use and how well it works. Here are some key points about the trial:[1]

  • It’s a randomized, double-blind, placebo-controlled study. This means participants are randomly assigned to different groups, and neither the patients nor the doctors know who is receiving the actual drug or a placebo (a harmless substance that looks like the real medicine).
  • The trial is testing two doses of Bexotegrast: 160 mg and 320 mg.
  • The study lasts for about 58 weeks for each participant, including:
    • 4 weeks of screening
    • 52 weeks of treatment
    • 2 weeks of follow-up after treatment ends

Potential Benefits of Bexotegrast

The main goals of the Bexotegrast trial are to see if it can:[1]

  1. Improve lung function: The primary aim is to see if Bexotegrast can slow down or stop the decline in forced vital capacity (FVC), which is a measure of how much air a person can exhale after taking a deep breath. This is an important indicator of lung health in IPF patients.
  2. Slow disease progression: Researchers are looking at whether Bexotegrast can delay the worsening of IPF symptoms and reduce the risk of hospitalization or death.
  3. Improve quality of life: The study is assessing if the drug can help reduce symptoms like breathlessness and cough, and improve overall well-being for patients with IPF.
  4. Reduce lung fibrosis: Using high-resolution CT scans, the researchers will check if Bexotegrast can decrease the amount of scarring in the lungs.

Who is Eligible for the Trial?

The trial has specific criteria for who can participate. Some key eligibility requirements include:[1]

  • Age 40 or older
  • Diagnosed with IPF within the last 7 years
  • Certain lung function test results that show moderate IPF
  • Patients already on other IPF treatments may be eligible if their dose has been stable for at least 12 weeks

There are also some conditions that would prevent a person from participating, such as having certain types of heart problems or other lung diseases.

Safety Considerations

As with any new medication, safety is a top priority in the Bexotegrast trial. The researchers are carefully monitoring for any side effects or adverse reactions throughout the study. Participants will have regular check-ups and tests to ensure their safety.[1]

It’s important to note that Bexotegrast is still an experimental drug. While it shows promise, more research is needed to fully understand its effects and determine if it’s safe and effective for widespread use in IPF patients.

Aspect Details
Drug Name Bexotegrast (PLN-74809)
Condition Treated Idiopathic Pulmonary Fibrosis (IPF)
Trial Phase Phase 2b/3
Main Objective Evaluate effect on forced vital capacity (FVC) at Week 52
Dosages Tested 160 mg and 320 mg
Trial Duration Approximately 58 weeks per participant
Key Eligibility Criteria Age ≥40, IPF diagnosis ≤7 years, specific lung function parameters
Study Design Randomized, double-blind, placebo-controlled
Secondary Objectives Disease progression, symptom improvement, lung fibrosis changes, safety and tolerability

FAQ

  • What is Bexotegrast? Bexotegrast, also known as PLN-74809, is a new drug being tested for the treatment of idiopathic pulmonary fibrosis (IPF). It is taken as a film-coated tablet and is designed to potentially slow down the progression of lung scarring in IPF patients.
  • What is the main goal of the Bexotegrast clinical trial? The main goal of the Bexotegrast clinical trial is to see how well it works compared to a placebo in changing the forced vital capacity (FVC) of people with IPF after 52 weeks of treatment. FVC is a measure of lung function.
  • Who can participate in the Bexotegrast clinical trial? Participants must be 40 years or older, have been diagnosed with IPF within the last 7 years, have certain lung function test results, and meet other specific criteria. Some people, such as those receiving treatment for pulmonary hypertension, may not be eligible.
  • How long does the clinical trial last? The total duration of the study for each participant is approximately 58 weeks. This includes a 4-week screening period, a 52-week treatment period, and a 2-week safety follow-up period.
  • What are the different doses of Bexotegrast being tested? The clinical trial is testing two doses of Bexotegrast: 160 mg and 320 mg. Some participants will receive one of these doses, while others will receive a placebo (a tablet that looks the same but contains no active drug).

Ongoing Clinical Trials on Bexotegrast

  • Study on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +5

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease characterized by scarring (fibrosis) of the lungs, which causes breathing difficulties and reduced lung function. The term 'idiopathic' means the cause is unknown.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath. It's an important measure of lung function used to assess the progression of IPF.
  • Placebo: A substance that looks like the real medication but contains no active drug. It's used in clinical trials to compare the effects of the actual drug against no treatment.
  • Randomized: A method used in clinical trials where participants are assigned by chance to different treatment groups. This helps ensure that the groups are similar and reduces bias.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual drug and who is receiving the placebo. This helps prevent bias in interpreting the results.
  • High-resolution computed tomography (HRCT): A detailed imaging technique used to examine the lungs and assess the extent of lung fibrosis in IPF patients.
  • Acute IPF exacerbation: A sudden worsening of IPF symptoms, which can be life-threatening and requires immediate medical attention.
  • Diffusing capacity for carbon monoxide: A test that measures how well oxygen moves from the lungs into the blood, which is often reduced in IPF patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-bexotegrast-for-patients-with-idiopathic-pulmonary-fibrosis/